Methyprylon

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Methyprylon
File:Methyprylon structure.svg
File:Methyprylon ball-and-stick.png
Clinical data
Trade namesNoludar, Dimerin, Noctan, Methyprylone, Noctan
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding60%
Elimination half-life6-16 hours
Identifiers
  • (RS)-3,3-diethyl-5-methylpiperidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H17NO2
Molar mass183.251 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • CCC1(CC)C(=O)NCC(C)C1=O
  • InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13) checkY
  • Key:SIDLZWOQUZRBRU-UHFFFAOYSA-N checkY
 NcheckY (what is this?)  (verify)

Methyprylon, or Noludar, is a sedative/tranquilizer and hypnotic central nervous system depressant of the piperidinedione derivative chemical class, first developed in the 1940s by Hoffmann-La Roche.[2] This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such as benzodiazepines.[3]

Methyprylon was withdrawn from the US market in June 1975 and the Canadian market in September 1990. Some other trade names are Noctan and Dimerin.

Adverse effects

[edit | edit source]

Side effects can include

  • skin rash
  • fever
  • depression
  • ulcers or sores in mouth or throat
  • unusual bleeding or bruising
  • fast heartbeat
  • CNS depressant effects, including mental depression and confusion, clumsiness, lack of coordination, respiratory depression, confusion, drowsiness, lethargy, swelling of feet or lower legs, dizziness
  • headache
  • double vision
  • constipation, diarrhea,
  • nausea and/or vomiting
  • ataxia, unusual weakness, clumsiness

Pharmacokinetics

[edit | edit source]

A study of single oral doses of 300 mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.[4]

A case report found that the pharmacokinetics of methyprylon were not concentration dependent in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.[5]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ US granted 2680116, Frick H, Lutz AH, "Piperidiones and Process for the Manufacture thereof", issued Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Hoffmann-La Roche 
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).